51 research outputs found

    Deformations of spacetime and internal symmetries

    Full text link
    Algebraic deformations provide a systematic approach to generalizing the symmetries of a physical theory through the introduction of new fundamental constants. The applications of deformations of Lie algebras and Hopf algebras to both spacetime and internal symmetries are discussed. As a specific example we demonstrate how deforming the classical flavor group SU(3)SU(3) to the quantum group SUq(3)Uq(su(3))SU_q(3)\equiv U_q(su(3)) (a Hopf algebra) and taking into account electromagnetic mass splitting within isospin multiplets leads to new and exceptionally accurate baryon mass sum rules that agree perfectly with experimental data.Comment: 5th International Conference on New Frontiers in Physics, Crete, Greece, July 6-14, 201

    Towards an emergent model of solitonic particles from non-trivial vacuum structure

    Full text link
    We motivate and introduce what we refer to as the principles of Lie-stability and Hopf-stability and see what the physical theories must look like. Lie-stability is needed on the classical side and Hopf-stability is needed on the quantum side. We implement these two principles together with Lie-deformations consistent with basic constraints on the classical kinematical variables to arrive at the form of a theory that identifies standard model fermions with quantum solitonic trefoil knotted flux tubes which emerge from a flux tube vacuum network. Moreover, twisted unknot fluxtubes form natural dark matter candidate

    The Physics of the B Factories

    Get PDF
    This work is on the Physics of the B Factories. Part A of this book contains a brief description of the SLAC and KEK B Factories as well as their detectors, BaBar and Belle, and data taking related issues. Part B discusses tools and methods used by the experiments in order to obtain results. The results themselves can be found in Part C

    Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

    Get PDF
    Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

    The Physics of the B Factories